The treatment landscape of lung cancer has drastically expanded over the last few years, adding novel drug classes and new combinations across the spectrum of disease. Because of this influx of data, oncologists and other clinicians involved in the care of patients with lung cancer are constantly challenged to stay current. Therefore, oncologists and other clinicians need additional education to improve their knowledge of the latest data and guidance for clinical practice. This series of 3 podcasts focusing on HER2-mutated non-small cell lung cancer (NSCLC), KRAS-mutated NSCLC, and malignant pleural mesothelioma is intended to provide information on the latest advancements and practical considerations for clinicians.